User login
Key clinical point: High-dose (HD) adalimumab maintenance regimen was associated with lower risk for treatment failure than standard dose (SD) regimen in patients with Crohn’s disease (CD) who failed antitumor necrosis factor (anti-TNF) therapy.
Major finding: The median time to treatment failure was 6.6 years vs. 3.0 years in the HD vs. SD group (log-rank test P = .006). The risk for treatment failure was lower in the HD vs. SD group (hazard ratio, 0.27; P = .002).
Study details: Findings are from a retrospective study of 117 patients with CD who failed anti-TNF and received adalimumab. Post induction, patients received either HD (40 mg weekly or 80 mg every other week; n=40) or SD (40 mg every other week; n=77) adalimumab maintenance regimen.
Disclosures: No information on funding was available. Some of the authors reported receiving honoraria, research grants/support, and/or consulting fees from various sources.
Source: Narula N et al. J Gastroenterol Hepatol. 2021 May 21. doi: 10.1111/jgh.15551.
Key clinical point: High-dose (HD) adalimumab maintenance regimen was associated with lower risk for treatment failure than standard dose (SD) regimen in patients with Crohn’s disease (CD) who failed antitumor necrosis factor (anti-TNF) therapy.
Major finding: The median time to treatment failure was 6.6 years vs. 3.0 years in the HD vs. SD group (log-rank test P = .006). The risk for treatment failure was lower in the HD vs. SD group (hazard ratio, 0.27; P = .002).
Study details: Findings are from a retrospective study of 117 patients with CD who failed anti-TNF and received adalimumab. Post induction, patients received either HD (40 mg weekly or 80 mg every other week; n=40) or SD (40 mg every other week; n=77) adalimumab maintenance regimen.
Disclosures: No information on funding was available. Some of the authors reported receiving honoraria, research grants/support, and/or consulting fees from various sources.
Source: Narula N et al. J Gastroenterol Hepatol. 2021 May 21. doi: 10.1111/jgh.15551.
Key clinical point: High-dose (HD) adalimumab maintenance regimen was associated with lower risk for treatment failure than standard dose (SD) regimen in patients with Crohn’s disease (CD) who failed antitumor necrosis factor (anti-TNF) therapy.
Major finding: The median time to treatment failure was 6.6 years vs. 3.0 years in the HD vs. SD group (log-rank test P = .006). The risk for treatment failure was lower in the HD vs. SD group (hazard ratio, 0.27; P = .002).
Study details: Findings are from a retrospective study of 117 patients with CD who failed anti-TNF and received adalimumab. Post induction, patients received either HD (40 mg weekly or 80 mg every other week; n=40) or SD (40 mg every other week; n=77) adalimumab maintenance regimen.
Disclosures: No information on funding was available. Some of the authors reported receiving honoraria, research grants/support, and/or consulting fees from various sources.
Source: Narula N et al. J Gastroenterol Hepatol. 2021 May 21. doi: 10.1111/jgh.15551.